The roles of cytochrome P450 in ischemic heart disease

Current Drug Metabolism

Volumn 12, Issue 6, 2011, Pages 526-532

  Sato, Motohiko ^a   Yokoyama, Utako ^a   Fujita, Takayuki ^a   Okumura, Satoshi ^a   Ishikawa, Yoshihioro ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Arachidonic acid; Cardiovascular disease; Cytochrome p450; Heart; Ischemia reperfusion; Pathophysiology

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2J2; EPOXYICOSATRIENOIC ACID; POTASSIUM CHANNEL; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SULFAPHENAZOLE;

ARTICLE; DISEASE ASSOCIATION; DRUG METABOLISM; GENETIC POLYMORPHISM; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PROTEIN EXPRESSION; REPERFUSION INJURY; SARCOLEMMA; SIGNAL TRANSDUCTION;

EID: 79957947630     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011795713715     Document Type: Article

References (87)

1. Capdevila, J.H.; Falck, J.R.; Harris, R.C., Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J. Lipid Res., 2000, 41, (2), 163-181. (Pubitemid 30117856)
2. Danielson, P.B., The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab., 2002, 3, (6), 561-597. (Pubitemid 35331660)
3. Ishikawa, Y.; Suzuki, S.; Otsu, K.; Ulucan, C.; Iwatsubo, K.; Eguchi, H., cAMP-mediated regulation of CYP enzymes and its application in chemotherapy. Drug Metab. Lett., 2007, 1, (3), 176-178.
4. Guengerich, F.P., Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J., 2006, 8, (1), E101-111.
5. Wang, B.; Yang, L.P.; Zhang, X.Z.; Huang, S.Q.; Bartlam, M.; Zhou, S.F., New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab. Rev., 2009, 41, (4), 573-643.
6. Pavek, P.; Dvorak, Z., Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab., 2008, 9, (2), 129-143. (Pubitemid 351461002)
7. Chaudhary, K.R.; Batchu, S.N.; Seubert, J.M., Cytochrome P450 enzymes and the heart. IUBMB Life, 2009, 61, (10), 954-960.
8. Thum, T.; Borlak, J., Gene expression in distinct regions of the heart. Lancet, 2000, 355, (9208), 979-983. (Pubitemid 30148264)
9. Choudhary, D.; Jansson, I.; Schenkman, J.B.; Sarfarazi, M.; Stoilov, I., Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch Biochem. Biophys., 2003, 414, (1), 91-100. (Pubitemid 36555449)
10. Minamiyama, Y.; Takemura, S.; Akiyama, T.; Imaoka, S.; Inoue, M.; Funae, Y.; Okada, S., Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett., 1999, 452, (3), 165-169. (Pubitemid 29301737)
11. Delozier, T.C.; Kissling, G.E.; Coulter, S.J.; Dai, D.; Foley, J.F.; Bradbury, J.A.; Murphy, E.; Steenbergen, C.; Zeldin, D.C.; Goldstein, J.A., Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab. Dispos., 2007, 35, (4), 682-688. (Pubitemid 46513273)
12. Tan, F.L.; Moravec, C.S.; Li, J.; Apperson-Hansen, C.; McCarthy, P.M.; Young, J.B.; Bond, M., The gene expression fingerprint of human heart failure. Proc. Natl. Acad. Sci. U S A, 2002, 99, (17), 11387-11392. (Pubitemid 34920935)
13. Aronow, B.J.; Toyokawa, T.; Canning, A.; Haghighi, K.; Delling, U.; Kranias, E.; Molkentin, J.D.; Dorn, G.W., 2nd, Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy. Physiol. Genomics, 2001, 6, (1), 19-28. (Pubitemid 33676471)
14. Wang, J.F.; Yang, Y.; Sullivan, M.F.; Min, J.; Cai, J.; Zeldin, D.C.; Xiao, Y.F.; Morgan, J.P., Induction of cardiac cytochrome p450 in cocaine-treated mice. Exp. Biol. Med. (Maywood), 2002, 227, (3), 182-188.
15. Yellon, D.M.; Hausenloy, D.J., Myocardial reperfusion injury. N. Engl. J. Med., 2007, 357, (11), 1121-1135.
16. Ferdinandy, P.; Schulz, R.; Baxter, G.F., Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol. Rev., 2007, 59, (4), 418-458.
17. Hausenloy, D.J.; Yellon, D.M., Preconditioning and postconditioning: united at reperfusion. Pharmacol. Ther., 2007, 116, (2), 173-191. (Pubitemid 47451505)
18. Sato, M.; Jiao, Q.; Honda, T.; Kurotani, R.; Toyota, E.; Okumura, S.; Takeya, T.; Minamisawa, S.; Lanier, S.M.; Ishikawa, Y., Activator of G protein signaling 8 (AGS8) is required for hypoxiainduced apoptosis of cardiomyocytes: role of G betagamma and connexin 43 (CX43). J. Biol. Chem., 2009, 284, (45), 31431-31440.
19. Seubert, J.M.; Zeldin, D.C.; Nithipatikom, K.; Gross, G.J., Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat., 2007, 82, (1-4), 50-59. (Pubitemid 44880163)
20. Granville, D.J.; Tashakkor, B.; Takeuchi, C.; Gustafsson, A.B.; Huang, C.; Sayen, M.R.; Wentworth, P., Jr.; Yeager, M.; Gottlieb, R.A., Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc. Natl. Acad. Sci. U S A, 2004, 101, (5), 1321-1326. (Pubitemid 38182687)
21. Morisseau, C.; Hammock, B.D., Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 311-333. (Pubitemid 40261808)
22. Spector, A.A.; Fang, X.; Snyder, G.D.; Weintraub, N.L., Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res., 2004, 43, (1), 55-90. (Pubitemid 37433867)
23. Seubert, J.M.; Sinal, C.J.; Graves, J.; DeGraff, L.M.; Bradbury, J.A.; Lee, C.R.; Goralski, K.; Carey, M.A.; Luria, A.; Newman, J.W.; Hammock, B.D.; Falck, J.R.; Roberts, H.; Rockman, H.A.; Murphy, E.; Zeldin, D.C., Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res., 2006, 99, (4), 442-450. (Pubitemid 44253701)
24. Monti, J.; Fischer, J.; Paskas, S.; Heinig, M.; Schulz, H.; Gosele, C.; Heuser, A.; Fischer, R.; Schmidt, C.; Schirdewan, A.; Gross, V.; Hummel, O.; Maatz, H.; Patone, G.; Saar, K.; Vingron, M.; Weldon, S.M.; Lindpaintner, K.; Hammock, B.D.; Rohde, K.; Dietz, R.; Cook, S.A.; Schunck, W.H.; Luft, F.C.; Hubner, N., Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat. Genet., 2008, 40, (5), 529-537. (Pubitemid 351601216)
25. Bieche, I.; Narjoz, C.; Asselah, T.; Vacher, S.; Marcellin, P.; Lidereau, R.; Beaune, P.; de Waziers, I., Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics, 2007, 17, (9), 731-742. (Pubitemid 47263068)
26. Capdevila, J.H.; Falck, J.R., The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem. Biophys. Res. Commun., 2001, 285, (3), 571-576. (Pubitemid 32924808)
27. Zeldin, D.C.; DuBois, R.N.; Falck, J.R.; Capdevila, J.H., Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch. Biochem. Biophys., 1995, 322, (1), 76-86.
28. Wu, S.; Chen, W.; Murphy, E.; Gabel, S.; Tomer, K.B.; Foley, J.; Steenbergen, C.; Falck, J.R.; Moomaw, C.R.; Zeldin, D.C., Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J. Biol. Chem., 1997, 272, (19), 12551-12559. (Pubitemid 27203348)
29. Wu, S.; Moomaw, C.R.; Tomer, K.B.; Falck, J.R.; Zeldin, D.C., Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem., 1996, 271, (7), 3460-3468. (Pubitemid 26065653)
30. Motoki, A.; Merkel, M.J.; Packwood, W.H.; Cao, Z.; Liu, L.; Iliff, J.; Alkayed, N.J.; Van Winkle, D.M., Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am. J. Physiol. Heart Circ. Physiol., 2008, 295, (5), H2128-2134.
31. Nithipatikom, K.; Moore, J.M.; Isbell, M.A.; Falck, J.R.; Gross, G.J., Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2006, 291, (2), H537-542. (Pubitemid 44175058)
32. Gross, G.J.; Hsu, A.; Falck, J.R.; Nithipatikom, K., Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J. Mol. Cell Cardiol., 2007, 42, (3), 687-691. (Pubitemid 46349123)
33. Seubert, J.; Yang, B.; Bradbury, J.A.; Graves, J.; Degraff, L.M.; Gabel, S.; Gooch, R.; Foley, J.; Newman, J.; Mao, L.; Rockman, H.A.; Hammock, B.D.; Murphy, E.; Zeldin, D.C., Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ. Res., 2004, 95, (5), 506-514. (Pubitemid 39180931)
34. Bodiga, S.; Zhang, R.; Jacobs, D.E.; Larsen, B.T.; Tampo, A.; Manthati, V.L.; Kwok, W.M.; Zeldin, D.C.; Falck, J.R.; Gutterman, D.D.; Jacobs, E.R.; Medhora, M.M., Protective actions of epoxyeicosatrienoic acid: dual targeting of cardiovascular PI3K and KATP channels. J. Mol. Cell Cardiol., 2009, 46, (6), 978-988.
35. Batchu, S.N.; Law, E.; Brocks, D.R.; Falck, J.R.; Seubert, J.M., Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J. Mol. Cell Cardiol., 2009, 46, (1), 67-74.
36. Katragadda, D.; Batchu, S.N.; Cho, W.J.; Chaudhary, K.R.; Falck, J.R.; Seubert, J.M., Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. J. Mol. Cell Cardiol., 2009, 46, (6), 867-875.
37. Lu, T.; Hoshi, T.; Weintraub, N.L.; Spector, A.A.; Lee, H.C., Activation of ATP-sensitive K(+) channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J. Physiol., 2001, 537, (Pt 3), 811-827. (Pubitemid 34026610)
38. Xu, W.; Liu, Y.; Wang, S.; McDonald, T.; Van Eyk, J.E.; Sidor, A.; O'Rourke, B., Cytoprotective role of Ca2+- activated K+ channels in the cardiac inner mitochondrial membrane. Science, 2002, 298, (5595), 1029-1033. (Pubitemid 35247311)
39. Campbell, W.B.; Gebremedhin, D.; Pratt, P.F.; Harder, D.R., Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res., 1996, 78, (3), 415-423. (Pubitemid 26072547)
40. Fisslthaler, B.; Popp, R.; Kiss, L.; Potente, M.; Harder, D.R.; Fleming, I.; Busse, R., Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature, 1999, 401, (6752), 493-497. (Pubitemid 29470209)
41. Fleming, I., Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol. Res., 2004, 49, (6), 525-533. (Pubitemid 38338662)
42. Okumura, S.; Vatner, D.E.; Kurotani, R.; Bai, Y.; Gao, S.; Yuan, Z.; Iwatsubo, K.; Ulucan, C.; Kawabe, J.; Ghosh, K.; Vatner, S.F.; Ishikawa, Y., Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation, 2007, 116, (16), 1776-1783. (Pubitemid 350287102)
43. Yang, B.; Graham, L.; Dikalov, S.; Mason, R.P.; Falck, J.R.; Liao, J.K.; Zeldin, D.C., Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol. Pharmacol., 2001, 60, (2), 310-320. (Pubitemid 32678296)
44. Dhanasekaran, A.; Gruenloh, S.K.; Buonaccorsi, J.N.; Zhang, R.; Gross, G.J.; Falck, J.R.; Patel, P.K.; Jacobs, E.R.; Medhora, M., Multiple antiapoptotic targets of the PI3K/Akt survival pathway areactivated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am. J. Physiol. Heart Circ. Physiol., 2008, 294, (2), H724-735. (Pubitemid 351253284)
45. Burley, D.S.; Hamid, S.A.; Baxter, G.F., Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev., 2007, 12, (3-4), 279-291. (Pubitemid 350176701)
46. Chaudhary, K.R.; Batchu, S.N.; Das, D.; Suresh, M.R.; Falck, J.R.; Graves, J.P.; Zeldin, D.C.; Seubert, J.M., Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved postischaemic recovery of heart contractile function. Cardiovasc. Res., 2009, 83, (2), 362-370.
47. Hunter, A.L.; Bai, N.; Laher, I.; Granville, D.J., Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction. Vascul. Pharmacol., 2005, 43, (4), 213-219. (Pubitemid 41586207)
48. Khan, M.; Mohan, I.K.; Kutala, V.K.; Kumbala, D.; Kuppusamy, P., Cardioprotection by sulfaphenazole, a cytochrome p450 inhibitor: mitigation of ischemia-reperfusion injury by scavenging of reactive oxygen species. J. Pharmacol. Exp. Ther., 2007, 323, (3), 813-821. (Pubitemid 350146050)
49. Doggrell, S.A., Inhibition of cardiac cytochrome P450: a new approach to cardiac ischaemia and reperfusion damage. Expert Opin. Ther. Targets, 2004, 8, (5), 491-493. (Pubitemid 39359653)
50. Archer, S.L.; Gragasin, F.S.; Wu, X.; Wang, S.; McMurtry, S.; Kim, D.H.; Platonov, M.; Koshal, A.; Hashimoto, K.; Campbell, W.B.; Falck, J.R.; Michelakis, E.D., Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12- epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation, 2003, 107, (5), 769-776. (Pubitemid 36222608)
51. Sasaki, M.; Ostanin, D.; Elrod, J.W.; Oshima, T.; Jordan, P.; Itoh, M.; Joh, T.; Minagar, A.; Alexander, J.S., TNF-alpha -induced endothelial cell adhesion molecule expression is cytochrome P-450 monooxygenase dependent. Am. J. Physiol. Cell Physiol., 2003, 284, (2), C422-428. (Pubitemid 36120080)
52. Fleming, I.; Michaelis, U.R.; Bredenkotter, D.; Fisslthaler, B.; Dehghani, F.; Brandes, R.P.; Busse, R., Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ. Res., 2001, 88, (1), 44-51. (Pubitemid 32064081)
53. Fichtlscherer, S.; Dimmeler, S.; Breuer, S.; Busse, R.; Zeiher, A.M.; Fleming, I., Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation, 2004, 109, (2), 178-183. (Pubitemid 38114136)
54. Forbes, R.A.; Steenbergen, C.; Murphy, E., Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ. Res., 2001, 88, (8), 802-809. (Pubitemid 32429976)
55. Cohen, M.V.; Yang, X.M.; Liu, G.S.; Heusch, G.; Downey, J.M., Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial K(ATP) channels. Circ. Res., 2001, 89, (3), 273-278. (Pubitemid 34132686)
56. Miners, J.O.; Birkett, D.J., Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol., 1996, 272, 139-145. (Pubitemid 26299876)
57. Kidd, R.S.; Straughn, A.B.; Meyer, M.C.; Blaisdell, J.; Goldstein, J.A.; Dalton, J.T., Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics, 1999, 9, (1), 71-80. (Pubitemid 29176726)
58. Bajpai, M.; Roskos, L.K.; Shen, D.D.; Levy, R.H., Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab. Dispos., 1996, 24, (12), 1401-1403. (Pubitemid 26427180)
59. Rettie, A.E.; Korzekwa, K.R.; Kunze, K.L.; Lawrence, R.F.; Eddy, A.C.; Aoyama, T.; Gelboin, H.V.; Gonzalez, F.J.; Trager, W.F., Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol., 1992, 5, (1), 54-59.
60. Stearns, R.A.; Chakravarty, P.K.; Chen, R.; Chiu, S.H., Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos., 1995, 23, (2), 207-215.
61. Miners, J.O.; Rees, D.L.; Valente, L.; Veronese, M.E.; Birkett, D.J., Human hepatic cytochrome P450 2C9 catalyzes the ratelimiting pathway of torsemide metabolism. J. Pharmacol. Exp. Ther., 1995, 272, (3), 1076-1081.
62. Rendic, S., Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev., 2002, 34, (1-2), 83-448. (Pubitemid 34311090)
63. Rendic, S.; Guengerich, F.P., Update information on drug metabolism systems-2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr. Drug Metab., 2010, 11, (1), 4-84.
64. Bylund, J.; Ericsson, J.; Oliw, E.H., Analysis of cytochrome P450 metabolites of arachidonic and linoleic acids by liquid chromatography- mass spectrometry with ion trap MS. Anal. Biochem., 1998, 265, (1), 55-68. (Pubitemid 28541793)
65. Dickmann, L.J.; Rettie, A.E.; Kneller, M.B.; Kim, R.B.; Wood, A.J.; Stein, C.M.; Wilkinson, G.R.; Schwarz, U.I., Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol., 2001, 60, (2), 382-387. (Pubitemid 32678304)
66. Dai, D.; Zeldin, D.C.; Blaisdell, J.A.; Chanas, B.; Coulter, S.J.; Ghanayem, B.I.; Goldstein, J.A., Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 2001, 11, (7), 597-607. (Pubitemid 32953585)
67. Visser, L.E.; van Schaik, R.H.; van Vliet, M.; Trienekens, P.H.; De Smet, P.A.; Vulto, A.G.; Hofman, A.; van Duijn, C.M.; Stricker, B.H., The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb. Haemost., 2004, 92, (1), 61-66. (Pubitemid 39010868)
68. Takanashi, K.; Tainaka, H.; Kobayashi, K.; Yasumori, T.; Hosakawa, M.; Chiba, K., CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics, 2000, 10, (2), 95-104. (Pubitemid 30193071)
69. Yasar, U.; Tybring, G.; Hidestrand, M.; Oscarson, M.; Ingelman- Sundberg, M.; Dahl, M.L.; Eliasson, E., Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab. Dispos., 2001, 29, (7), 1051-1056. (Pubitemid 32605922)
70. Miners, J.O.; Birkett, D.J., Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol., 1998, 45, (6), 525-538. (Pubitemid 28270907)
71. Higashi, M.K.; Veenstra, D.L.; Kondo, L.M.; Wittkowsky, A.K.; Srinouanprachanh, S.L.; Farin, F.M.; Rettie, A.E., Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama, 2002, 287, (13), 1690-1698. (Pubitemid 34289221)
72. Scordo, M.G.; Aklillu, E.; Yasar, U.; Dahl, M.L.; Spina, E.; Ingelman- Sundberg, M., Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol., 2001, 52, (4), 447-450. (Pubitemid 32939447)
73. Sullivan-Klose, T.H.; Ghanayem, B.I.; Bell, D.A.; Zhang, Z.Y.; Kaminsky, L.S.; Shenfield, G.M.; Miners, J.O.; Birkett, D.J.; Goldstein, J.A., The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 1996, 6, (4), 341-349. (Pubitemid 26288624)
74. Inoue, K.; Yamazaki, H.; Imiya, K.; Akasaka, S.; Guengerich, F.P.; Shimada, T., Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'- hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 1997, 7, (2), 103-113. (Pubitemid 27261842)
75. Yasar, U.; Lundgren, S.; Eliasson, E.; Bennet, A.; Wiman, B.; de Faire, U.; Rane, A., Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun., 2002, 299, (1), 25-28. (Pubitemid 35366030)
76. Chehal, M.K.; Granville, D.J., Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction. Can. J. Physiol. Pharmacol., 2006, 84, (1), 15-20. (Pubitemid 44011946)
77. Yasar, U.; Bennet, A.M.; Eliasson, E.; Lundgren, S.; Wiman, B.; De Faire, U.; Rane, A., Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics, 2003, 13, (12), 715-720. (Pubitemid 38429249)
78. Lee, C.R.; North, K.E.; Bray, M.S.; Couper, D.J.; Heiss, G.; Zeldin, D.C., CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet. Genomics, 2007, 17, (5), 349-358. (Pubitemid 46608542)
79. Kaur-Knudsen, D.; Bojesen, S.E.; Nordestgaard, B.G., Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals. Pharmacogenomics J., 2009, 9, (5), 327-332.
80. Haschke-Becher, E.; Kirchheiner, J.; Trummer, O.; Grunbacher, G.; Kainz, A.; Boehm, B.O.; Marz, W.; Renner, W., Impact ofCYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. Pharmacogenomics, 2010, 11, (10), 1359-1365.
81. Spiecker, M.; Darius, H.; Hankeln, T.; Soufi, M.; Sattler, A.M.; Schaefer, J.R.; Node, K.; Borgel, J.; Mugge, A.; Lindpaintner, K.; Huesing, A.; Maisch, B.; Zeldin, D.C.; Liao, J.K., Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation, 2004, 110, (15), 2132-2136. (Pubitemid 39372490)
82. Elbekai, R.H.; El-Kadi, A.O., Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol. Ther., 2006, 112, (2), 564-587. (Pubitemid 44488710)
83. Zhang, Y.; El-Sikhry, H.; Chaudhary, K.R.; Batchu, S.N.; Shayeganpour, A.; Jukar, T.O.; Bradbury, J.A.; Graves, J.P.; DeGraff, L.M.; Myers, P.; Rouse, D.C.; Foley, J.; Nyska, A.; Zeldin, D.C.; Seubert, J.M., Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol., 2009, 297, (1), H37-46.
84. Halpert, J.; Naslund, B.; Betner, I., Suicide inactivation of rat liver cytochrome P-450 by chloramphenicol in vivo and in vitro. Mol. Pharmacol., 1983, 23, (2), 445-452. (Pubitemid 13116870)
85. Rendic, S.; Di Carlo, F.J., Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev., 1997, 29, (1-2), 413-580. (Pubitemid 27293618)
86. Scripture, C.D.; Pieper, J.A., Clinical pharmacokinetics of fluvastatin. Clin. Pharmacokinet., 2001, 40, (4), 263-281. (Pubitemid 32458153)
87. Ye, D.; Zhou, W.; Lu, T.; Jagadeesh, S.G.; Falck, J.R.; Lee, H.C., Mechanism of rat mesenteric arterial KATP channel activation by 14,15-epoxyeicosatrienoic acid. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, (4), H1326-1336.